These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

196 related items for PubMed ID: 2299212

  • 1. Decreased in vitro susceptibility to zidovudine of HIV isolates obtained from patients with AIDS.
    Land S, Terloar G, McPhee D, Birch C, Doherty R, Cooper D, Gust I.
    J Infect Dis; 1990 Feb; 161(2):326-9. PubMed ID: 2299212
    [Abstract] [Full Text] [Related]

  • 2. HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy.
    Larder BA, Darby G, Richman DD.
    Science; 1989 Mar 31; 243(4899):1731-4. PubMed ID: 2467383
    [Abstract] [Full Text] [Related]

  • 3. Effect of stage of disease and drug dose on zidovudine susceptibilities of isolates of human immunodeficiency virus.
    Richman DD, Grimes JM, Lagakos SW.
    J Acquir Immune Defic Syndr (1988); 1990 Mar 31; 3(8):743-6. PubMed ID: 2114476
    [Abstract] [Full Text] [Related]

  • 4. [Inhibition of human immunodeficiency virus replication by azidothymidine (Azitidín Lachema) in cultured cells].
    Schmidtmayerová H, Mayer V.
    Bratisl Lek Listy; 1993 Feb 31; 94(2):76-80. PubMed ID: 7689030
    [Abstract] [Full Text] [Related]

  • 5. Potent and selective activity of a new carbocyclic nucleoside analog (carbovir: NSC 614846) against human immunodeficiency virus in vitro.
    Vince R, Hua M, Brownell J, Daluge S, Lee FC, Shannon WM, Lavelle GC, Qualls J, Weislow OS, Kiser R.
    Biochem Biophys Res Commun; 1988 Oct 31; 156(2):1046-53. PubMed ID: 2847711
    [Abstract] [Full Text] [Related]

  • 6. Zidovudine-resistant and -sensitive HIV-1 isolates from patients on drug therapy: in vitro studies evaluating level of replication-competent viruses and cytopathogenicity.
    Tremblay M, Rooke R, Wainberg MA.
    AIDS; 1992 Dec 31; 6(12):1445-9. PubMed ID: 1492930
    [Abstract] [Full Text] [Related]

  • 7. In-vitro resistance to zidovudine and alpha-interferon in HIV-1 isolates from patients: correlations with treatment duration and response.
    Edlin BR, St Clair MH, Pitha PM, Whaling SM, King DM, Bitran JD, Weinstein RA.
    Ann Intern Med; 1992 Sep 15; 117(6):457-60. PubMed ID: 1503348
    [Abstract] [Full Text] [Related]

  • 8. Susceptibility testing by polymerase chain reaction DNA quantitation: a method to measure drug resistance of human immunodeficiency virus type 1 isolates.
    Eron JJ, Gorczyca P, Kaplan JC, D'Aquila RT.
    Proc Natl Acad Sci U S A; 1992 Apr 15; 89(8):3241-5. PubMed ID: 1565615
    [Abstract] [Full Text] [Related]

  • 9. AZT resistance in isolates of HIV.
    Richman DD.
    Immunodefic Rev; 1991 Apr 15; 2(4):315-8. PubMed ID: 2059436
    [Abstract] [Full Text] [Related]

  • 10. Incidence of zidovudine-resistant human immunodeficiency virus isolated from patients before, during, and after therapy.
    Land S, McGavin C, Lucas R, Birch C.
    J Infect Dis; 1992 Nov 15; 166(5):1139-42. PubMed ID: 1402026
    [Abstract] [Full Text] [Related]

  • 11. Zidovudine resistance predicted by direct detection of mutations in DNA from HIV-infected lymphocytes.
    Larder BA, Kellam P, Kemp SD.
    AIDS; 1991 Feb 15; 5(2):137-44. PubMed ID: 1709563
    [Abstract] [Full Text] [Related]

  • 12. Zidovudine.
    Powderly WG.
    Mo Med; 1989 Nov 15; 86(11):741-3. PubMed ID: 2682195
    [Abstract] [Full Text] [Related]

  • 13. Development of resistance to zidovudine in HIV strains isolated from CD4+ lymphocytes and plasma during therapy.
    Nielsen C, Gøtzsche PC, Nielsen CM, Gerstoft J, Vestergaard BF.
    Antiviral Res; 1992 Jun 15; 18(3-4):303-16. PubMed ID: 1358026
    [Abstract] [Full Text] [Related]

  • 14. Triple whammy. Will an AIDS therapy live up to its advance billing?
    Rennie J.
    Sci Am; 1993 May 15; 268(5):18, 22. PubMed ID: 7683141
    [No Abstract] [Full Text] [Related]

  • 15. A rapid and simple colorimetric test for the study of anti-HIV agents.
    Schwartz O, Henin Y, Marechal V, Montagnier L.
    AIDS Res Hum Retroviruses; 1988 Dec 15; 4(6):441-8. PubMed ID: 2464361
    [Abstract] [Full Text] [Related]

  • 16. Targets for antiviral therapy of human immunodeficiency virus infection.
    Jeffries DJ.
    J Infect; 1989 Jan 15; 18 Suppl 1():5-13. PubMed ID: 2464649
    [Abstract] [Full Text] [Related]

  • 17. [Antiretroviral therapy in Switzerland 1991].
    Hirschel B, Vanhems P.
    Schweiz Med Wochenschr; 1991 Aug 24; 121(34):1187-93. PubMed ID: 1925447
    [Abstract] [Full Text] [Related]

  • 18. Use of evolutionary limitations of HIV-1 multidrug resistance to optimize therapy.
    Chow YK, Hirsch MS, Merrill DP, Bechtel LJ, Eron JJ, Kaplan JC, D'Aquila RT.
    Nature; 1993 Feb 18; 361(6413):650-4. PubMed ID: 7679778
    [Abstract] [Full Text] [Related]

  • 19. Viral load, viral phenotype modification, zidovudine susceptibility and reverse transcriptase mutations during the first 6 months of zidovudine monotherapy in HIV-1-infected people.
    Rusconi S, De Pasquale MP, Mainini F, Bulgheroni E, Kurtagic S, Gori A, Violin M, Zanchetta N, Moroni M, Balotta C, Galli M.
    Antivir Ther; 1996 Dec 18; 1(4):211-9. PubMed ID: 11324823
    [Abstract] [Full Text] [Related]

  • 20. Zalcitabine. A review of its pharmacology and clinical potential in acquired immunodeficiency syndrome (AIDS).
    Whittington R, Brogden RN.
    Drugs; 1992 Oct 18; 44(4):656-83. PubMed ID: 1281077
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.